AGGRASTAT® (tirofiban HCl)

Dosing and Administration

100 mL & 250 mL single dose pre-mixed IntraVia® container

Weight		30-Minute Loading Dose		Maintenance Infusion	12-Hour Infusion	18-Hour Infusion	24-Hour Infusion
Lb	**Kg**	**Rate** (mL/hr)	**Volume** (mL)	**Rate** (mL/hr)	**Bags Needed**	**Bags Needed**	**Bags Needed**
66-82	30-37	16	8	4	1 red	1 red	1 blue
83-100	38-45	20	10	5	1 red	1 red	1 blue
101-119	46-54	24	12	6	1 red	1 blue	1 blue
120-137	55-62	28	14	7	1 red	1 blue	1 blue
138-155	63-70	32	16	8	1 blue	1 blue	1 blue
156-174	71-79	36	18	9	1 blue	1 blue	1 blue
175-192	80-87	40	20	10	1 blue	1 blue	1 blue + 1 red
193-210	88-95	44	22	11	1 blue	1 blue	1 blue + 1 red
211-229	96-104	48	24	12	1 blue	1 blue	1 blue + 1 red
230-247	105-112	52	26	13	1 blue	1 blue + 1 red	1 blue + 1 red
248-265	113-120	56	28	14	1 blue	1 blue + 1 red	2 blue
266-283	121-128	60	30	15	1 blue	1 blue + 1 red	2 blue
284-302	129-137	64	32	16	1 blue	1 blue + 1 red	2 blue
303-319	138-145	68	34	17	1 blue	1 blue + 1 red	2 blue
320-337	146-153	72	36	18	1 blue + 1 red	2 blue	2 blue

1 red = 100-mL single-dose IntraVia® bag* 1 blue = 250-mL single-dose IntraVia® bag

For Patients with Acute Coronary Syndrome (Unstable Angina or Non-ST-segment Elevation MI)

1. Loading dose for 30 minutes: 0.4 mcg/kg/min
2. Maintenance infusion: 0.1 mcg/kg/min

2007 ACC/AHA Guidelines recommend use of GP IIb/IIIa inhibitors in high-risk UA/NSTEMI patients[1]:

"The current evidence base and expert opinion suggest that a GP IIb/IIIa inhibitor should be given before angiography for high-risk, troponin-positive patients."

Additional high-risk patient types that may benefit from early administration of a GP IIb/IIIa inhibitor include:

- Patients with diabetes mellitus
- Patients with dynamic ST-segment changes
- Patients with ongoing ischemic discomfort

Dosage Adjustments for Patients with Renal Insufficiency

In clinical studies, patients with severe renal insufficiency (creatinine clearance <30 mL/min) showed decreased plasma clearance of AGGRASTAT®.

The loading infusion and maintenance infusion should be decreased by 50% in patients with creatinine clearance <30 mL/min.

Using the Cockcroft-Gault equation, creatinine clearance is calculated as:

Males

$$\frac{(140\text{-age})\ (\text{body wt}^{\dagger}\ \text{in kg})}{72\ (\text{serum creatinine})}$$

Females

$$\frac{(140\text{-age})\ (\text{body wt}^{\dagger}\ \text{in kg})\ (0.85)}{72\ (\text{serum creatinine})}$$

AGGRASTAT is removed by hemodialysis.

Contraindicated in patients with:

- Know hypersensitivity to any component of the product
- Active internal bleeding or a history of bleeding diathesis within the previous 30 days
- A history of intracranial hemorrhage, intracranial neoplasm, arteriovenous malformation, or aneurysm
- A history of thrombocytopenia following prior exposure to AGGRASTAT
- History of stroke within 30 days or any history of hemorrhagic stroke
- Major surgical procedure or severe physical trauma within the previous month
- History, symptoms, or findings suggestive of aortic dissection
- Severe hypertension (systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg)
- Concomitant use of another parenteral GP IIb/IIIa inhibitor
- Acute pericarditis

Compatibilities:

- May be administered in the same intravenous line as heparin, dopamine, lidocaine, potassium chloride, and PEPCID® (famotidine) injection
- Should not be administered in the same intravenous line as diazepam

Storage

- Store at 25°C (77°F) with excursions permitted between 15-30C (59-86F) (see USP Controlled Room Temperature)
- Do not freeze
- Protect from light during storage

Administration of AGGRASTAT® is associated with an increase in bleeding events classified as both major and minor bleeding events by criteria developed by the Thrombolysis in Myocardial Infarction (TIMI) study group. Most major bleeding associated with AGGRASTAT occurs at the arterial access site for cardiac catheterization. Fatal bleeding events have been reported. Caution should be employed when AGGRASTAT is used with other drugs that affect hemostasis.

Please see accompanying full Prescribing Information. For additional information concerning Aggrastat, including dosing concerns, please call Medicure Pharma General Inquires at (800) 509-0544.

*IntraVia is a registered trademark of Baxter International, Inc.
†Ideal body weight may be used

1. Adapted from ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. *Circulation* 2007;116:803-877

AGGRASTAT is a registered trademark of Medicure Pharma.
©2008 Medicure Pharma. All rights reserved. Printed in Canada. January 2008

AGGRASTAT® (tirofiban HCl)